Your shopping cart is currently empty

NS3623 is an activator of human ether-a-go-go-related gene (hERG) potassium channels with a dual mode of action, also acting as an inhibitor of hERG1 channels. It activates the IKr and Ito currents and exhibits an antiarrhythmic effect.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $34 | In Stock | In Stock | |
| 10 mg | $54 | In Stock | In Stock | |
| 25 mg | $111 | In Stock | In Stock | |
| 50 mg | $180 | In Stock | In Stock | |
| 100 mg | $268 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $37 | In Stock | In Stock |
| Description | NS3623 is an activator of human ether-a-go-go-related gene (hERG) potassium channels with a dual mode of action, also acting as an inhibitor of hERG1 channels. It activates the IKr and Ito currents and exhibits an antiarrhythmic effect. |
| In vitro | Administering NS3623 (5 μM) significantly enhances the tail current magnitude in isolated canine cardiomyocytes, corroborating earlier evidence that this compound augments IKr. Specifically, NS3623 boosts IKr tail currents by 60% in normal Mid cells and by 68% in cells cultured for 48 hours, at a +50 mV activating pulse. Furthermore, although the baseline IKr in cells cultured for 48 hours markedly declines compared to freshly isolated cells—from 0.47 ± 0.08 pA/pF to 0.28 ± 0.06 pA/pF—NS3623 application elevates IKr in these cultured Mid cells. An analysis of the current-voltage (I-V) relationship for IKr tail current reveals that NS3623 increases current density in Mid cells cultured for both one and two days. |
| In vivo | NS3623 (30 mg/kg; i.v.; lasting for 3 minutes) shortens the corrected QT interval by 25 ± 4% in anaesthetized guinea pigs. At 50 mg/kg, NS3623 immediately reduces the QTcF interval and remains significantly shortened for approximately 30 minutes, also shortening the QT interval by 30 ± 6% in conscious guinea pigs [1]. |
| Molecular Weight | 427.18 |
| Formula | C15H10BrF3N6O |
| Cas No. | 343630-41-1 |
| Smiles | FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nnn[nH]2)c1 |
| Relative Density. | 1.759 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 9.17 mg/mL (21.47 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.